{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:59:57Z","timestamp":1789721997699,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T00:00:00Z","timestamp":1357603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-11","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T16:23:10Z","timestamp":1357748590000},"source":"Crossref","is-referenced-by-count":70,"title":["Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)"],"prefix":"10.1186","volume":"13","author":[{"given":"Arash","family":"Naeim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J","family":"Henk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Badre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Deeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,8]]},"reference":[{"issue":"9","key":"3624_CR1","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005, 103 (9): 1916-1924. 10.1002\/cncr.20983.","journal-title":"Cancer"},{"issue":"2","key":"3624_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004, 100 (2): 228-237. 10.1002\/cncr.11882.","journal-title":"Cancer"},{"issue":"10","key":"3624_CR3","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006, 106 (10): 2258-2266. 10.1002\/cncr.21847.","journal-title":"Cancer"},{"issue":"12","key":"3624_CR4","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","volume":"34","author":"GH Lyman","year":"1998","unstructured":"Lyman GH, Kuderer N, Greene J, Balducci L: The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998, 34 (12): 1857-1864. 10.1016\/S0959-8049(98)00222-6.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"3624_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00003495-200262001-00005","volume":"62","author":"GH Lyman","year":"2002","unstructured":"Lyman GH, Kuderer NM: Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs. 2002, 62 (Suppl 1): 65-78.","journal-title":"Drugs"},{"issue":"6","key":"3624_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O: Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005, 10 (6): 427-437. 10.1634\/theoncologist.10-6-427.","journal-title":"Oncologist"},{"issue":"3","key":"3624_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mdm525","volume":"19","author":"D Weycker","year":"2008","unstructured":"Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G: Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008, 19 (3): 454-460.","journal-title":"Ann Oncol"},{"issue":"2","key":"3624_CR8","first-page":"44","volume":"5","author":"D Weycker","year":"2007","unstructured":"Weycker D, Malin J, Glass A, Oster G: Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol. 2007, 5 (2): 44-45.","journal-title":"J Support Oncol"},{"key":"3624_CR9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3892\/etm.2011.312","volume":"2","author":"MBPC Schilling","year":"2011","unstructured":"Schilling MBPC, Deeter RG: Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med. 2011, 2: 859-866.","journal-title":"Exp Ther Med"},{"key":"3624_CR10","doi-asserted-by":"crossref","unstructured":"Kozma CDM, Chia V, Legg L, Barron R: Trends in Neutropenia-Related Inpatient Events. J Oncol Pract. Epub ahead of print, Jan. 31, 2012","DOI":"10.1200\/JOP.2011.000360"},{"issue":"19","key":"3624_CR11","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006, 24 (19): 3187-3205. 10.1200\/JCO.2006.06.4451.","journal-title":"J Clin Oncol"},{"key":"3624_CR12","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. http:\/\/www.nccn.org ]"},{"key":"3624_CR13","first-page":"742","volume-title":"A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients","author":"CV Morrison VA","year":"2004","unstructured":"Morrison VA CV, Fridman M, Delgado DJ: A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients. 2004, Alexandria, Virginia: Proceedings of the American Society of Clinical Oncology Annual Meeting: 2004: 742. Abstract 8068, 742- http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2445 ,"},{"issue":"1","key":"3624_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003, 14 (1): 29-35. 10.1093\/annonc\/mdg019.","journal-title":"Ann Oncol"},{"issue":"9","key":"3624_CR15","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/1042819031000103953","volume":"44","author":"A Grigg","year":"2003","unstructured":"Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W: Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 2003, 44 (9): 1503-1508. 10.1080\/1042819031000103953.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3624_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O\u2019Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002, 13 (6): 903-909. 10.1093\/annonc\/mdf130.","journal-title":"Ann Oncol"},{"issue":"3","key":"3624_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol. 2002, 20 (3): 727-731. 10.1200\/JCO.20.3.727.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3624_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","volume":"21","author":"JM Vose","year":"2003","unstructured":"Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, et al: Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003, 21 (3): 514-519. 10.1200\/JCO.2003.03.040.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3624_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG: Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?. Ann Pharmacother. 2006, 40 (3): 402-407. 10.1345\/aph.1G516.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"3624_CR20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","volume":"13","author":"VA Morrison","year":"2007","unstructured":"Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J: Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007, 13 (4): 337-348.","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"3624_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.clinthera.2009.05.019","volume":"31","author":"D Weycker","year":"2009","unstructured":"Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G: Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther. 2009, 31 (5): 1069-1081. 10.1016\/j.clinthera.2009.05.019.","journal-title":"Clin Ther"},{"key":"3624_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1185\/03007995.2010.536527","volume":"27","author":"HTK Tan","year":"2011","unstructured":"Tan HTK, Hurley D, Daniel G, Barron R, Malin J: Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011, 27: 79-86. 10.1185\/03007995.2010.536527.","journal-title":"Curr Med Res Opin"},{"key":"3624_CR23","doi-asserted-by":"crossref","unstructured":"Weycker DMJ, Barron R, Edelsberg J, Kartashov A, Oster G: Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol. Epub ahead of print, March 2, 2011","DOI":"10.1097\/COC.0b013e31820dc075"},{"key":"3624_CR24","unstructured":"Department of Health and Human Services, Code of Federal Regulations: Code Fed Regul Public Welfare 1995. Protection of human subjects. Washington DC, http:\/\/www.hhs.gov\/ohrp\/policy\/ohrpregulations.pdf . Title 45(Sections 46\u2013101 to 46\u2013409):Unknown"},{"key":"3624_CR25","first-page":"1936","volume":"110","author":"Department of Health and Human Services, Code of Federal Regulations","year":"1996","unstructured":"Department of Health and Human Services, Code of Federal Regulations: Health Insurance Portability and Accountability Act of 1996. Public Law 104\u2013191. US Statut Large. 1996, 110: 1936-2103. http:\/\/aspe.hhs.gov\/admnsimp\/pl104191.htm ,","journal-title":"US Statut Large"},{"key":"3624_CR26","unstructured":"WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. [ http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html ]"},{"issue":"11","key":"3624_CR27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005, 43 (11): 1130-1139. 10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"issue":"1","key":"3624_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1548-5315(11)70766-5","volume":"1","author":"BV Fortner","year":"2004","unstructured":"Fortner BV, Okon TA, Zhu L, Tauer K, Moore K, Templeton D, Schwartzberg L: Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice. Commun Oncol. 2004, 1 (1): 23-28. 10.1016\/S1548-5315(11)70766-5.","journal-title":"Commun Oncol"},{"issue":"Suppl 5","key":"3624_CR29","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S1098-3597(06)80054-2","volume":"8","author":"GH Lyman","year":"2006","unstructured":"Lyman GH: Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2006, 8 (Suppl 5): S12-S18.","journal-title":"Clin Cornerstone"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T15:37:35Z","timestamp":1644075455000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3624"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-11","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,8]]},"article-number":"11"}}